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Background: Biological systems are exquisitely poised to respond and adjust to challenges, including damage.
However, sustained damage can overcome the ability of the system to adjust and result in a disease phenotype, its
underpinnings many times elusive. Unraveling the molecular mechanisms of systems biology, of how and why it
falters, is essential for delineating the details of the path(s) leading to the diseased state and for designing
strategies to revert its progression. An important aspect of this process is not only to define the function of a gene
but to identify the context within which gene functions act. It is within the network, or pathway context, that the
function of a gene fulfills its ultimate biological role. Resolving the extent to which defective function(s) affect the
proceedings of pathway(s) and how altered pathways merge into overpowering the system’s defense machinery
are key to understanding the molecular aspects of disease and envisioning ways to counteract it. A network-centric
approach to diseases is increasingly being considered in current research. It also underlies the deployment of
disease pathways at the Rat Genome Database Pathway Portal. The portal is presented with an emphasis on disease
and altered pathways, associated drug pathways, pathway suites, and suite networks.
Results: The Pathway Portal at the Rat Genome Database (RGD) provides an ever-increasing collection of interactive
pathway diagrams and associated annotations for metabolic, signaling, regulatory, and drug pathways, including
disease and altered pathways. A disease pathway is viewed from the perspective of networks whose alterations are
manifested in the affected phenotype. The Pathway Ontology (PW), built and maintained at RGD, facilitates the
annotations of genes, the deployment of pathway diagrams, and provides an overall navigational tool. Pathways
that revolve around a common concept and are globally connected are presented within pathway suites; a suite
network combines two or more pathway suites.
Conclusions: The Pathway Portal is a rich resource that offers a range of pathway data and visualization, including
disease pathways and related pathway suites. Viewing a disease pathway from the perspective of underlying altered
pathways is an aid for dissecting the molecular mechanisms of disease.
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Pathways and the Pathway Ontology
Molecular networks or pathways represent sets of interac-
tions and reactions that together form a functional unit.
While the physical boundaries of such units are in many
instances fluid, their delineation by the research commu-
nity establishes a paradigm for studying the working of
biomolecules within a context. These can be the sets of re-
actions and interactions that underlie the transformation
of compounds, those that are initiated or triggered by a
signaling event, or those that aim to maintain the normal
status quo of cells and tissue. As such, they define the
metabolic, signaling, and regulatory pathways, respect-
ively. However, when one or more components within
such sets are deviant, their effects can lead to an overall
disturbance of the system. This is the realm of altered
pathways whose combined effects may merge into the dis-
eased state—the disease pathway. Finally, there are the
sets of reactions and interactions that illustrate the re-
sponses of the system to the treatment intended to handle
the diseased state. They constitute the drug pathways that
include the pharmacokinetics and pharmacodynamics
drug pathways—how the system processes/metabolizes
the drug and how the drug affects the system, the drug-
target interaction(s) and response(s), respectively. Drugs
and other compounds can elicit adverse effects, at times
severe enough to be toxic; such reactions offer a toxicoge-
nomic perspective and are viewed as regulatory response
networks. The various categories/types of pathways are or-
ganized within a hierarchical structure in the Pathway
Ontology (PW) [1], developed and maintained at the Rat
Genome Database (RGD) [2,3]. The five nodes of the ontol-
ogy are metabolic, regulatory, signaling, disease, and drug
pathways. As necessary, terms for the altered version(s) of
pathways are provided. The ontology allows for the stan-
dardized annotation of rat, human, and mouse genes to
pathway terms. It also enables the deployment of inter-
active pathway diagram pages and allows for links between
diagrams, ontology, and gene report pages, between con-
nected pathways within diagrams, and between related
pathways in pathway suites and suite networks. As such, it
is the essential navigational tool of the Pathway Portal
and, overall, within RGD [4,5]. PW has also been instru-
mental for the building of pipelines to bring in pathway
annotations done by other groups: the Pathway Inter-
action Database (PID) [6] pipeline for human gene anno-
tations, extended to the rat and mouse orthologs, and the
Kyoto Encyclopedia of Genes and Genomes (KEGG) [7,8]
pipeline, for rat, mouse, and human gene annotations.
Pathway entries, as available at the sites, were mapped to
PW terms as synonyms, and the genes associated with
them were matched to RGD rat, human, or mouse genes
using the Entrez gene ID and symbol [1]. Currently, these
two pipelines are no longer running as PID has sinceretired and KEGG has changed its license; however, the
annotations, as last brought in, are still available. Building
the two pipelines benefited the ongoing development of
the ontology, as more terms were added in order to pro-
vide for the mapping. In particular, the disease pathway
node saw a substantial increase through the addition of
terms for infectious diseases, substance abuse, and im-
mune system diseases. More pipelines are planned to be
built in the future. The cancer pathway entry and the pan-
creatic cancer pathway entry in the disease pathway node
are shown in Figure 1A, B. In the ontology browser, A
stands for annotations, D stands for diagrams, and the
light versus dark shade(s) distinguish between annotations
and/or diagrams to children or to term(s), respectively. A
plus sign in front of a term designates the presence of
children for that term.
Disease and altered pathways—a network approach to
diseases
A disease pathway, as opposed to the clinical, gene-
centric view of the condition, offers a network-centric
view—an approach increasingly being considered by sci-
entists. Interestingly, despite a wealth of information on
mutated genes, the number of those considered ‘driver’
genes in cancer (genes that can promote or ‘drive’ tumori-
genesis) is relatively small. Collectively, they are found in a
set of important pathways such as the Ras-driven Erk1/2
and phosphatidylinositol 3-kinase-Akt signaling, those
mediated by receptor tyrosine kinases (RTK), or those that
are involved in cell cycle and apoptosis, DNA damage
control, chromatin modification, and transcriptional regu-
lation [9,10]. Although the rest of the mutant genes are
considered ‘passengers’, their presence and faulty interac-
tions could, at least in principle, augment in some fashion
the negative impact of ‘driver’ genes and, as such, contrib-
ute to the altered pathways leading to disease. Given the
role these pathways normally play, their alterations can
easily fuel the ‘hallmarks’ of cancer proposed by Hanahan
and Weinberg: sustaining proliferative signaling, evading
growth suppressors, activating invasion and metastasis,
enabling replicative immortality, inducing angiogenesis,
and resisting cell death [11]. In addition to variant genes
and their associated dysfunctional pathways, deregulations
stemming from sources other than protein coding genes
such as those associated with microRNAs (miRNAs) and
other non-coding elements or from sources other than se-
quence variation such as those at the epigenetic level can
and do contribute to the disease phenotype. Abnormal
chromatin modification as well as the up- and down-
regulated expression of miRNA in tumor tissues com-
pared to normal ones have been reported [10,12]. Systems
level, high-throughput, and -omics approaches to the
study and understanding of disease initiation and progres-
sion are being considered [13,14]. Disease pathways are
Figure 1 The Pathway Ontology disease node and entries examples. (A) The disease node and entries within. (B) The ‘pancreatic cancer
pathway’ entry and position within the ontology.
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they are presented as sets/collections of altered pathways.
The provision of terms for altered pathways and the
representation of disease pathways and diagrams as col-
lections of altered pathways are features unique to PW
and its use at RGD [1,4,5]. The organization of individual
disease pathway terms follows the structure of disease vo-
cabularies with respect to the type of disease, organ, orFigure 2 Pancreatic cancer pathway diagram page. The interactive pat
pathways implicated in the condition are shown as gray rectangles, and th
each pathway are shown color-coded (the default color is red). The icon fo
to a page where several miRNAs are listed with additional links and referentissue location, such that navigating this node can be both
easy and meaningful to the user [see Figure 1]. Within an
interactive diagram page for a disease pathway, those
pathways known to be altered in the condition are repre-
sented with the culprit genes color-coded. As an example,
the pancreatic cancer pathway is shown in Figure 2. Also
color-coded are the culprit genes in a diagram for the al-
tered version of the pathway [Figure 3B]. Connections orhway diagram page for the ‘pancreatic cancer pathway’. The altered
ey link to their respective ontology report pages. Culprit genes within
r the microRNAs (miRNAs) potentially implicated in the condition links
ces. The disease icon links to the Cancer Disease Portal in RGD.
Figure 3 Hypoxia-inducible factor pathway. (A) The regular ‘hypoxia inducible factor pathway’. (B) The ‘altered hypoxia inducible
factor pathway’.
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removed and/or changed, as appropriate, compared to the
normal pathway proceedings [compare Figure 3A, B]. Any
connected pathway shown on a diagram as a gray rect-
angle [see for instance Figures 2 and 3B] links to its ontol-
ogy report and, from there, to a diagram, if one exists.
Every gene entry links to its gene report page. Other links
are provided for entries that group together several
components/elements such as complexes, target genes,
differentially expressed miRNAs, or other candidate genes.
These are pages created within a content management
system (CMS), and the individual elements in a page have
links to corresponding report and/or other pages [see for
instance ‘potential pancreatic cancer miRNA’ in Figure 2
and ‘Tceb1 recruited complex’ or ‘Hif target genes’ in
Figure 3]. Links to drug or chemical compound ontology
reports or sites or to pertinent disease portals at RGD are
provided, as applicable. Every diagram page contains a
synopsis with various links, and in the case of an altered
pathway, a direct link to its normal version. The diagram
page contains the list of genes in the pathway—by species
(rat, human, mouse) or all, and tabular lists for genes in
the pathway that have annotations to disease, pathway,
and/or phenotype terms (the lists can be toggled). Finally,
each page contains references that link to the PubMed ab-
stract entry and a graph view of the path(s) to the term in
the ontology [Figure 4] (graph not shown in Figure 4).
PW is in the form of a directed acyclic graph (DAG),
meaning that a more specific, child term can have more
than one, more general, parent term (i.e., there can be
more than one path to a term). Reviews and associated re-
search literature are used to build the pathway diagrams
and descriptions. They are also used to annotate the hu-
man, mouse, and rat genes to the pathway terms. The rat
genes are also functionally annotated using the Gene
Ontology (GO). As mentioned, a direct link in the synop-
sis of an altered pathway to its normal version is provided
and within an altered pathway the affected connections/
relations are deleted, as necessary. Viewing the altered and
normal pathway ‘side-by-side’ provides an instant snap-
shot of the affected gene-gene relationship(s) and their
possible outcomes. Culprit genes are annotated to disease
and altered pathway terms and also to the appropriate
disease term in the disease ontology (RDO) used at
RGD. RGD uses several ontologies for the annotation of
genes, QTL, and strains—some are developed by out-
side sources and in some cases RGD may contribute
terms (RDO is the RGD version of the MEDIC disease
vocabulary from the Comparative Toxicogenomics Data-
base (CTD)) [15]; others, like PW, are developed at RGD
(see for instance [16]).
Resources such as KEGG [8], the Small Molecule
Pathway Database (SMPDB) [17], and Reactome [18] offer
pathway diagrams, including disease pathways, along withlinks to gene entries and other pertinent information.
However, the portrayal of disease pathways as the collec-
tion of altered pathways associated with a particular devi-
ant phenotype, the use of a dedicated pathway ontology to
annotate gene products and for use as a navigational tool
conferring the ability to ‘travel’ the road of connected
pathways, along with the provision of pathway suites and
suite networks, are all distinctive features of the RGD
Pathway Portal.
Results and discussion
The RGD Pathway Portal houses an ever-increasing col-
lection of interactive diagram pages for metabolic, regu-
latory, signaling, drug, and disease and associated altered
pathways along with related pathway suites and suite
networks for those pathways that globally revolve around
a common concept. Most of the current disease pathway
diagrams are pertinent to various cancer types such as
colorectal, endometrial, lung, pancreatic, prostate, or renal
cancer [see Figure 2]. Diagrams for associated drugs in-
clude cisplatin—used in the treatment of several tumors,
the anti-estrogen tamoxifen and aromatase inhibitors—
used in the treatment of breast cancers, axitinib—used in
the treatment of renal cell carcinoma, and gefitinib—used
in the treatment of non-small cell lung cancer. As chemi-
cals, including drugs, can exert adverse side effects, at
times severe enough to be toxic, response pathway terms
and diagrams are used to capture these potentially toxic
outcomes and reactions. For instance, the above men-
tioned drug cisplatin is known to exert severe kidney,
neurotoxic, and ototoxic effects—the latter can lead to
deafness and is particularly severe in young children.
Bisphenol A (BPA) is a compound used in the production
of many types of plastics, the lining of food containers,
medical and dental devices, and thermal paper. It is also
an endocrine-disrupting chemical (EDC) which interacts
with several nuclear and hormone receptors but primarily
targets estrogen receptors and has been implicated in the
etiology of numerous diseases, including cancer. To illus-
trate the utility of the RGD pathway suite, the BPA re-
sponse pathway links to estrogen signaling and estrogen
signaling links to the biosynthesis of estradiol and both
the estrogen signaling and estradiol biosynthesis have links
from the anti-estrogen drug pathway (which has links to
the individual drug pathways). It is the ‘Estrogen Path-
way Suite’ that brings everything together—estrogen
signaling and estradiol biosynthesis, the biosynthesis of
cholesterol—the precursor of all steroid hormones, and
signaling by the sterol regulatory element-binding pro-
tein which controls cholesterol and lipid homeostasis,
along with the anti-estrogen drug, and the BPA that tar-
gets the estrogen receptor. In another group of related
pathways, the folate cycle [see Figure 4] and accom-
panying folate-mediated one-carbon metabolic pathway,
Figure 4 (See legend on next page.)
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Figure 4 The elements of an interactive pathway diagram page using the folate cycle metabolic pathway as an example. (A) The
synopsis of the pathway is shown at the top of the page with the option of viewing the entire text; the diagram of the pathway is below the
description. (B) The genes in the pathway are shown by species in tabular form and there are various link options. (C) Genes in the pathway that
have disease annotations are shown in tabular form that can be toggled between the alphabetically listed diseases with the associated genes
shown to the right (default) and the alphabetically listed genes with the associated diseases shown to the right. (D) Genes in the pathway that
have pathway annotations are shown in tabular form that can be toggled between the alphabetically listed pathways with the associated genes
shown to the right (default) and the alphabetically listed genes with the associated pathways shown to the right. The last section of the diagram
page contains the reference list and a view of the ontology tree (not shown).
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cysteine cycles—together interdependent upon each
other and each further branching into de novo purine
biosynthesis, the transsulfuration or the remethylation
pathways of homocysteine metabolism, as needed, or
polyamine biosynthesis are all members of the ‘Methio-
nine, Homocysteine, Folate and Related Metabolites Path-
way Suite’ [Figure 5]. The methionine cycle produces the
almost universal methyl donor—S-adenosylmethionione
(SAM) used in the methylation of DNA, histones, and
other molecules. Aberrant gene methylation is observed
in many cancer types. An example of a suite network is
the tripartite ‘Balancing Blood Pressure Regulatory Mech-
anisms Suite Network’ featuring three suites for pathways
with a role in mediating an increase or a decrease in blood




Pancreatic cancer is one of the most aggressive cancer
types which despite sustained scientific and clinical ef-
forts continues to have a less than 5% overall 5-year sur-
vival rate. It is the fourth leading cause of cancer-related
death and both men and women are affected. Pancreatic
ductal adenocarcinoma (PDAC) is the predominant form
with neoplastic precursor lesions such as pancreatic
intraepithelial neoplasia (PanIN) graded stage I to III,
converging into PDAC and ultimately invasion and me-
tastasis. A major genetic driver is Kras of the Ras family
believed to be an initiator of PDAC and a promoter of
its development and progression. Activating mutations
are present in >90% of PDAC and can be found as early
as PanIN grade I and even in normal pancreas. KRAS
activation found in the early stages of pancreatic cancer
is followed by inactivation of the cell cycle regulator
CDKN2A (95%) also in the earlier stages, and inactiva-
tion of TP53 (75%) and SMAD4 (55%) in the later
stages. The CDKN2A gene codes for two non-identical
proteins of which the p16 or p16/Ink4a product is the
cyclin-dependent kinase inhibitor and cell cycle regula-
tor and the p14 or p14/Arf product is a p53-activating
tumor suppressor. The inactivating mutations in PDAC
involve the p16/Ink4a gene product [19-21]. However,p14/Arf mutations are associated with other cancer
types, and the two protein products act in connected
pathways—p53 signaling promotes, as necessary, cell cycle
arrest, apoptosis, or senescence and is also a negative
regulator of p14/Arf expression [22,23]. Studies, large-
scale genomic studies in particular, indicate that many im-
portant cellular pathways are deregulated in pancreatic
cancer, those involving the above mentioned genes as well
as others [24-26] and references therein. These pathways
are major players in the regulation of cell growth, differen-
tiation, proliferation, and/or survival, such as the extra-
cellular signal-regulated Raf/Mek/Erk (ERK1/2) pathway
downstream of Kras, the Smad-dependent transforming
growth factor-beta (TGF-beta) pathway, or the epidermal
growth factor/neuregulin (EGF) signaling pathway. Other
involved genes are known tumor suppressors such as
Tp53 (P53), whose signaling bridges DNA damage re-
sponse to cell cycle arrest or apoptosis, or important
regulators such as Pten in the phosphatidylinositol
3-kinase-Akt (PI3K-Akt) signaling pathway and Cdkn2a
in the G1/S transition pathway of the cell cycle. PI3K-
Akt may also be downstream of oncogenic Kras in
PDAC. Signaling by Hedgehog proteins or hepatocyte
growth factor (SF/HGF) play important developmental
roles, and both pathways are deregulated in pancreatic
cancer. Finally, other involved pathways are integrin-
mediated signaling, with important roles in adhesion,
and canonical Wnt signaling, with important roles in
development. Alterations in components of chromatin
modification and remodeling pathways have also been
identified. Prominent pathways shown to be altered in
the condition are represented in the ‘pancreatic cancer
pathway’ diagram page [see Figure 2]. While the sub-
stantial number of pathways observed to be affected
may be the result of large-scale experimental approaches,
it is nonetheless possible that this is a feature particular to
pancreatic cancer and as such it may underlie the extreme
aggressiveness of this malignancy. The combined effect
of these altered pathways can ‘meet’ most if not all the
above mentioned ‘hallmarks’ of cancer as put forward by
Hanahan and Weinberg [11]. A number of these path-
ways, particularly those involving Kras, Pten, or EGF, are
also deregulated in many other cancer types. Ras proteins
were the first oncogenes identified in human cancers,
Figure 5 (See legend on next page.)
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Figure 5 The Methionine, Homocysteine, Folate and Related Metabolites Pathway Suite. An overall depiction of the interconnectedness of
methionine, homocysteine, and folate metabolic cycles along with other pathways within and/or branching off accompanied by a brief
description. Snapshots of the individual pathways within the suites are provided with brief descriptions that link—from the title, image, and
description—to the respective interactive pathway diagram page.
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a much lesser extent, mutations in the closely related Hras
or Nras genes. Kras confers stem-like properties on cer-
tain cell types, Kras deletion leads to death during em-
bryogenesis in mice, and it is in pancreatic cancer that the
activating Kras mutations are the most frequent [27]. miR-
NAs, which primarily inhibit the translation of target
genes, are aberrantly expressed in pancreatic cancer as
well as other cancer types. Many miRNAs are shown to
be both up- and down-regulated in pancreatic cancer
resulting in multiple effects such as chemoresistance,
proliferation, survival, invasion, and metastasis [12].
Early detection of pancreatic cancer has proven difficult.
Aberrant DNA methylation and other epigenetic alter-
ations are observed in many cancer types, including
pancreatic cancer. Epigenetic markers may provide a
means for earlier detection of pancreatic cancer [28].
Pancreatic cancer may be an extreme case but it is
nonetheless intriguing why so many mutations and as-
sociated altered pathways converge on this organ and its
malignancy and why they do display a preferential as
well as a temporal pattern.
Prostate cancer pathway
Unlike pancreatic cancer with its plethora of altered
pathways, in the case of prostate cancer, the main culprit
is the androgen receptor (AR) of the androgen signaling
pathway. A deregulated phosphatidylinositol 3-kinase-Akt
pathway also contributes with loss or inactivating muta-
tions in the Pten regulator and, to a lesser extent, amplifi-
cation or activating mutations of the catalytic subunit
Pik3ca. Deletions at the p53 locus in the p53 pathway have
also been seen in prostate cancer samples [29]. Normal
androgen signaling plays an essential role in the develop-
ment and maintenance of the male phenotype and repro-
ductive functions and in a range of other processes. The
steroid hormone AR belongs to the nuclear receptor fam-
ily. Once activated by hormone binding—testosterone or
its more potent metabolite dihydrotestosterone (DHT),
AR translocates to the nucleus to regulate the expression
of its target genes. In the altered pathway leading to
prostate cancer, the androgen receptor displays an intri-
guing altered and mutational behavior, mostly treatment-
induced. Reduction of testosterone levels leads to changes
in gene copy number and also in increased transcription
of the receptor. Thus, trace amounts of the ligand are
enough to set its signaling pathway in motion. Complete
elimination of plasma testosterone initially abrogatesreceptor activity, followed in time by various mechanisms
which result in ligand-independent androgen receptor sig-
naling. Increased phosphorylation of the receptor, expres-
sion of splice variants that do not have the ligand binding
domain, mutations that allow the receptor to bind to and
be activated by non-traditional ligands including antago-
nists, and altered expression of coregulators, steroid bio-
synthetic enzymes, and/or the receptor transcriptional
program all contribute to testosterone-independent recep-
tor activity [30-34]. Alterations in the NCOA2 coactivator
and NCOR2 corepressor and in chromatin regulatory ele-
ments have been reported [29]. Steroid hormones share a
core biosynthetic pathway that branches into the indi-
vidual steroid biosynthesis in given tissues via tissue-
specific expression of terminal enzymes; in prostate
cancer, changes in enzyme expression circumvent the
initial testosterone depletion [31]. Gene fusion between
androgen receptor-regulated genes and members of the
E26 transformation-specific (ETS) family of oncogenic
transcription factors is a signature feature found in ~50%
of cases. Fusion between the Tmprss2 gene and the Erg
member of the ETS family is common in prostate cancer.
The gene rearrangements have been mostly noticed in pri-
mary prostate cancer while the alterations/mutations of
the receptor have been associated with the treatment-
resistant, metastatic prostate tumors. The PI3K-Akt and
p53 alterations are observed in both primary and meta-
static prostate cancer. Mutations in a number of other ele-
ments are being unraveled and await further investigation
with respect to their role in the initiation and/or progres-
sion of prostate tumors [29,32,33]. In the altered androgen
signaling and prostate cancer pathways, the androgen
receptor becomes a ligand-independent or antagonist-
induced, constitutively active transcription factor.
Renal cell cancer pathway
Like prostate cancer, renal cell cancer (RCC), of which
the clear cell RCC (ccRCC) is the most common type,
results from a relatively small number of alterations in
known pathways [Figure 6]. The main contributor in this
case is an altered hypoxia-inducible factor (HIF) pathway
where mutations in von Hippel-Lindau (VHL) protein
render the pathway constitutively active and are found
in ~90% of RCC tumors [35]. The HIF pathway is con-
sidered a master regulator of oxygen homeostasis. HIF is
a heterodimer composed of a constitutively expressed
subunit beta also known as the aryl-hydrocarbon recep-
tor (Arnt) with roles in several transcription pathways
Figure 6 Renal cell cancer pathway. The interactive pathway diagram page for the ‘renal cell cancer pathway’ with the associated altered
pathways and culprit genes. The icons for the miRNAs with potential implications, other candidate genes, and drug pathways, link to pages with
related information and links within.
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regulated by oxygen and also in an oxygen-independent
manner. Both subunits are members of the basic helix-
loop-helix (bHLH) and PER-ARNT-SIM (PAS) domain-
containing family of transcription factors. Under normoxic
conditions, the HIF proteins are subject to proline and as-
paragine hydroxylation carried out by enzymes that are
oxygen-dependent and require iron and 2-oxoglutarate for
activity [36]. The modified prolines are recognized by
VHL which targets HIF for proteasomal degradation; themodified asparagine blocks the interaction of HIF with
transcriptional activators [see Figure 3A]. There are three
HIF alpha isoforms of which alpha 1 and 2 are thought to
be the primary VHL targets. Both isoforms are believed to
play a role in RCC, but it is the alpha 2 protein that ap-
pears to have the predominant role in tumorigenesis [37].
The two isoforms have common and also distinct targets
with angiogenic genes being under the control of both iso-
forms while genes involved in cell proliferation, dediffer-
entiation, and invasion are under the control of alpha 2
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thought to underlie distinct morbidity and mortality phe-
notypes. Mutations in components of the citric acid cycle
(tricarboxylic acid or TCA cycle) create a pseudohypoxic
environment that impacts on Hif modification, stabilizes
the protein, and renders the pathway active, even when
the VHL protein may be wild-type [39]. In addition,
large-scale sequencing experiments have identified gen-
etic changes in a number of genes whose protein prod-
ucts have epigenetic roles such as histone methylation
and demethylation in ~15% of RCC cases. Also, truncat-
ing mutations in the PBRM1 gene known as BAF180 (a
component of a chromatin remodeling complex) were
found in ~41% of cases [37]. The exact role these muta-
tions have in the context of RCC remains to be estab-
lished. It is possible that they affect, in some fashion,
the transcriptional activity of HIF. It is worth mention-
ing that, in the case of the alpha 1 isoform, studies show
binding and regulation of expression of several Jumonji
domain-containing histone lysine demethylases [40]. VHL
is a tumor suppressor gene first identified in patients with
VHL disease—a rare hereditary cancer syndrome that ex-
hibits vascularized tumors of the retina and other tissues.
RCC, however, is primarily a sporadic condition, where
bi-allelic inactivation of VHL due to chromosomal loss,
mutations, or hypermethylation accounts for much of its
incidence [41,42].
In RCC, as in the case of prostate cancer with altered
androgen signaling, HIF has become an unregulated,
condition-independent, constitutively active transcription
factor. However, unlike the androgen receptor pathway
with its rather distinct expression and functional range,
the HIF pathway is ubiquitous, yet its alteration is local-
ized. VHL, the dominant contributor to RCC, is rarely
mutated in other sporadic tumors.
Drug and drug/compound responses—axitinib, cisplatin,
and bisphenol A
Several drugs have been developed for the treatment of
RCC (see ‘Renal cell cancer pathway’); their targets in-
clude the vascular endothelial growth factor (VEGF) and
its receptors downstream of Hif-mediated transcription
or the mTOR pathway which regulates HIF translation
[35]. Most drugs target the VGEF receptors and among
them is axitinib—a drug selective for VEGF receptors 1,
2, and 3 that competes with ATP for binding into the
ATP binding pocket of the receptor. The drug pathway
presents an overall depiction of axitinib action which
includes the pharmacokinetics and pharmacodynamics
pathways, targeted pathways, and side effects [Figure 7A].
In many cases, the pharmacokinetics arm of the drug
pathway shows the human genes as many experiments
are carried out in human liver microsomes and the en-
zymes involved in drug metabolism have, in many cases,broad substrate specificity and/or have not been well
conserved throughout evolution.
Unlike axitinib, which is selective for a particular
target and is primarily used in the treatment of RCC,
cisplatin is a drug used in the treatment of numerous
cancer types. It is a platinating agent whose main target
is agreed to be DNA where cisplatin and other platinat-
ing drugs form various DNA adducts. The DNA lesions
activate the DNA damage response (DDR) system which,
among a number of responses, can promote apoptosis
and as such is toxic to proliferating cancer cells. The
pharmacokinetics and pharmacodynamics of cisplatin are
presented in a single diagram as the drug does not have a
specific target [Figure 7B]. Cisplatin is the most potent of
the platinating agents and is also the most toxic [43].
Neurotoxic, ototoxic, and renal effects have been reported,
with the ototoxic effect being the most severe. The hear-
ing loss associated with cisplatin treatment can lead to
deafness and is particularly severe in children. The inci-
dence of ototoxicity is reported to be 23%–50% for adults
and greater than 50% for children. Cisplatin exerts similar
effects in non-cancer cells as it does in cancer cells.
Increased exposure/accumulation, changes in transporter
levels and/or DNA repair genes, and epigenetic or regula-
tory differences may render certain cells more prone to
undergo apoptosis, adding to the observed toxic effects.
The cisplatin response pathway shows these effects and
lists the transporters that are thought to be responsible in
various tissues [Figure 8A].
Like cisplatin, BPA can form DNA adducts, but its pri-
mary targets are nuclear and hormone receptors, mainly
the estrogen receptors. BPA is used in the production of
many types of plastics, the lining of food containers, med-
ical and dental devices, and thermal paper. The high levels
of BPA production are responsible for its widespread pres-
ence in the environment. In addition, BPA can also be
found in food due to its leaching out of containers. BPA
binds the ESR1 and ESR2 nuclear estrogen receptors and
also the G protein-coupled estrogen receptor GPER. BPA
can induce rapid activation of the Erk1/2 pathway via
GPER in breast cancer; it may affect various immune re-
sponses and has been implicated in the etiology of many
diseases and disorders [44] [Figure 8B]. Most compounds
and drugs exert negative effects; the distinction between
adverse effects and toxicity is one of response, i.e., the
relative steepness of the response curve. As in the altered
and disease pathways, the diagrams attempt to capture the
molecular underpinnings of drug metabolism and of
drug-target interactions or the implications of drug and/
or chemical toxicity
Estrogen pathway suite
Estrogen signaling is essential for female sexual develop-
ment and reproductive functions and plays important
Figure 7 Drug pathways. (A) The overall drug pathway for axitinib with associated pharmacokinetics and pharmacodynamics pathways and
targeted pathways. (B) The interactive pathway diagram for the drug cisplatin.
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Figure 8 Drug response pathways. (A) The diagram page for the cisplatin response pathway showing the toxic effects of the drug and the
genes that may be responsible for its accumulation. (B) The diagram page for the bisphenol A (BPA) response pathway showing its uses, targets,
and effects.
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brain function [see Figure 9]. Estrogen activates two nu-
clear receptors, ESR1 and ESR2, the G protein-coupled
estrogen receptor GPER, and the fraction of membrane-
tethered ESR receptors. Estrogen signaling affects the
expression of many genes. Deregulation of estrogen sig-
naling is implicated in the etiology of breast cancer, and
signaling is constitutively active in more than 50% of
cases. The estrogen signaling pathway is a target for the
development of anti-estrogen drugs. Pharmacologically,
two approaches are being used to counteract estrogen-
driven proliferation and promote tumor regression. One is
targeting the receptors, and tamoxifen is an example of a
selective estrogen receptor modulator (SERM). Tamoxifen
binds competitively to the estrogen receptors acting as an
antagonist in breast cancer cells and as a partial agonist inFigure 9 The estrogen pathway suite. The pathways revolving around e
individual pathways are shown as snapshots with links to the respective dibone and cardiovascular systems. The pharmacokinetics
of tamoxifen are complex with both primary and second-
ary metabolites being formed whose potencies are greater
than that of the parent compound. The metabolites are
inactivated via glucuronidation and sulfation, the former
is the main route. The other pharmacological approach is
targeting the synthesis of estrogen. Estradiol, the main
C18 estrogen, is primarily synthesized in the ovaries and,
like all steroid hormones, is derived from cholesterol. The
steroid hormones biosynthetic pathway consists of a core
of common reactions that branches out into the pro-
duction of individual hormones through the action of
end terminal enzymes whose expression is confined to
particular tissues. In the case of estrogens—estradiol (E2)
and estrone (E1), this involves CYP19A1, a cytochrome
P450 member, known as aromatase. Three generations ofstrogen are shown with their connections and a brief description. The
agram page from the title, image, and accompanying description.
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generation currently being used. The inhibitors are further
classified as type I or type II depending on whether the in-
hibition is irreversible or reversible. Cholesterol, the pre-
cursor of steroid hormones and an essential component of
cell membranes and lipid rafts, is under the control of the
sterol regulatory element-binding protein (SREBP) signal-
ing pathway. The SREBF (SREBP) proteins represent a
subfamily of basic helix-loop-helix leucine zipper tran-
scription factors whose signaling regulates cholesterol and
lipid homeostasis and, in turn, is regulated by the levels of
lipids. The nuclear and G protein-coupled estrogen recep-
tors are also targets of BPA whose actions have been im-
plicated in the etiology of many diseases, disorders, and
affected processes. The various pathways revolving around
estrogen are brought together within the ‘Estrogen Path-
way Suite’ to provide an instant glimpse of their associa-
tions while individual examination provides a tool for
studying and exploring the underlying molecular events.
Conclusions and future developments
A disease pathway brings together associated altered
pathways and culprit genes within, along with deregu-
lated miRNAs and other putative candidate genes, to
provide a unique view of the possible molecular mecha-
nisms underlying the condition. Normal processes are
hijacked, harnessed, and modulated by tumor cells to
serve their proliferative and invasive needs, as posited by
Hanahan and Weinberg [11]. The case studies presented
here centered on malignancies and featured a number of
special examples: the extreme case of pancreatic cancer
with its many altered pathways; prostate cancer with few
contributors and whose main culprit, despite its intri-
guing therapy-induced resistance response, can be ratio-
nalized by virtue of specific expression and function; and
renal cell cancer, also with few contributors, but whose
main culprit cannot be readily explained by virtue of ex-
pression and function alone. Despite the identity of al-
tered pathways being different, constitutive signaling as
well as deregulated expression of coding and non-coding
genes, activation of oncogenes, and silencing of tumor
suppressors are shared features. However, there are also
distinctive features and they raise questions. For instance,
many of the pathways altered in pancreatic cancer are
known to be oncogenic in other cancer types—as an ex-
ample, TP53 is the most commonly mutated gene in can-
cer. However, it is KRAS that has the highest mutation
incidence in pancreatic cancer—twice its occurrence in
cancer of the colon or small intestine, followed in decreas-
ing order by endometrium and lung cancers and much
lower in neoplasms of other tissues. Why is KRAS prefer-
entially mutated in pancreatic cancer and why does this
member of Ras have the highest overall mutagenic propen-
sities relative to the other two, closely related Rasmembers, HRAS and NRAS? Differential codon usage in
KRAS might underlie its higher mutagenic rate than its
Ras cousins and distinct mutations may confer distinct
functional behaviors upon the mutant proteins and prompt
different outcomes, but they do not explain what triggers
the frequency of mutations in and their association with
different tissues [27]. In a similar vein, one may ask why
somatic mutations in the VHL protein are primarily associ-
ated with renal cell cancer or why diminishing levels of tes-
tosterone prompt the kind of mutations that render the
androgen receptor ligand-independent.
Interestingly, the pancreatic acinar cells and the most
abundant cell type, under certain conditions such as in-
jury and accompanying inflammation, can acquire plastic
capabilities [45]. Findings suggest that acinar cells may
be the cells of origin for PanIN lesions and renal ductal
adenocarcinoma. These findings await further investiga-
tion to be firmly established. However, one is tempted to
wonder whether the proneness of KRAS to mutate may
in some fashion be aided or activated within a challenged
pancreatic tissue milieu, perhaps further promoting its
plasticity and the instantiation of mutations in other
genes. Likewise, do the unique features of the filtering sys-
tem the kidney represents make it more vulnerable to un-
wanted hypoxic responses which would be easy to ‘satisfy’,
by just silencing VHL? Are the reproductive tissues more
likely to be affected by infection, and does a yet to be iden-
tified infectious agent confer upon the androgen receptor
its features, reminiscent of acquired resistance?
The provision of diagrams offers a means to quickly
visualize the individual aspects of given pathways and, in
the case of disease pathways, to inspect the underlying
altered pathways, how their unfolding differs from the
regular ones, what features are shared, and which ones
may be unique. Having access to a large collection of
disease and associated altered pathways enables the user
to quickly inspect, compare, and identify aspects that may
be unique or aspects that may be intriguing. As such, it
can prompt asking new questions or redefining previous
ones, lead to the search for new or revised venues of
inquiry, and overall help further the efforts aimed at deci-
phering the mechanisms that determine the initiation and
progression of disease. Future work will focus on expand-
ing the repertoire of published diagrams for disease and
altered pathways and associated drug and response path-
ways. Also, pathways underlying epigenetics and transcrip-
tional programs, which are at the heart of differential gene
expression in which genes get expressed and/or spliced at
certain times in certain locations, likely play a role in the
issues raised above. In addition, new pipelines and new
features/entries of individual diagrams, such as those for
genes with non-synonymous variants in the sequenced rat
strains and genes and variant structural models, are sched-
uled to be implemented. The overall increase of the
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annotations for the rat, human, and mouse genes repre-
sent an ongoing process in the multifaceted Pathway
Portal project.
Methods
The Pathway Ontology is being developed using the OBO
ontology editor, developed by the Gene Ontology Consor-
tium [46]. The pathway diagrams are being built using
Pathway Studio software, version 9, from Elsevier [47].
The pathway diagram pages are made using a pathway
curation tool web application developed at RGD [48]. The
methodology for building the pathway pipelines is detailed
in Petri et al. [1].
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